March 6th Options Now Available For CVS Health

CVS (current price $81.57) option ideas: a sell-to-open $73 put (bid $0.50) would set an effective purchase basis of $72.50, is ~11% out-of-the-money, carries a 78% probability of expiring worthless and would yield 0.68% (5.81% annualized) if it does. A covered-call using the $85 call (bid $1.20) against stock bought at $81.57 is ~4% out-of-the-money, has a 60% chance to expire worthless and would produce a 5.68% total return if called by the March 6 expiration (premium-only YieldBoost 1.47%, 12.49% annualized). Implied volatilities are 46% (put) and 36% (call) versus a trailing 12‑month volatility of 30%.

Analysis

Market structure: Options pricing shows asymmetric downside fear in CVS (stock $81.57) — 73 puts bid $0.50 (IV 46%, 78% chance to expire OTM) while 85 calls bid $1.20 (IV 36%, 60% OTM). That implies the market is willing to pay ~+16 vol points for downside protection versus upside; this benefits income/option sellers and hedgers, and hurts buyers of protection. Short-term liquidity will favor blocked, cash-secured put and covered-call flow, increasing supply of stock into ETFs if assigned.

Risk assessment: Tail risks include PBM/regulatory reimbursement shocks or a broader retail/pharmacy margin squeeze that could knock CVS down >20% (low-prob, high-impact). Immediate (days–weeks): option decay and IV re-pricing around events; short-term (1–3 months): assignment risk into March 6 expiration; long-term (quarters): secular pressures from pricing/reimbursement and one-off M&A/regulatory actions. Hidden dependencies: correlation with healthcare services (Aetna/insurer exposure) and Rx reimbursement policy; catalysts include February CMS updates or earnings.

Trade implications: Tactical income trades are favored given IV > realized vol (46% vs 30%). Preferred plays: (a) cash-secured put sell at 73 to establish long at $72.50 basis with a 78% statistical OTM probability; (b) covered-call overlay at 85 for ~5.7% upside+premium to Mar 6 if already long. Use spreads to cap assignment (e.g., 73/70 put spread) and size positions to 1–3% portfolio each.

Contrarian angle: Consensus income trade ignores regulatory tail and skew; downside IV premium suggests smart money hedging. Reaction is underdone on mandated reimbursement risk and overdone on short-term assignment fear; historical parallels: pharmacy multiples compress after reimbursement headlines (2015–2017), creating buying opportunities post-15–25% drawdowns. Unintended consequence: heavy put-selling could force long inventory into the market on assignment, pressuring spot price near strike.

Key Decisions for Investors

• Sell cash-secured CVS Mar 6 73 puts (bid ~$0.50) for up to 2% portfolio exposure — effective basis $72.50/share; size such that max cash commitment ≤2% of portfolio; if assigned, plan to hold >=3 months unless fundamentals change.
• If long CVS, sell Mar 6 85 covered calls (collect ~$1.20) on up to 3% portfolio weight; let be called at $85 for ~5.7% gross return or buy-to-close if CVS drops below $76 (protect downside).
• If wanting asymmetric risk control, sell 73/70 put spreads (cap max loss ~$3/share) sized 1–2% portfolio to capture IV premium while limiting assignment risk; close or roll if IV falls >10 vol points or stock trades <70.
• Establish a directional pair: go long CVS and short WBA (1:1 dollar basis) for 1–2% net exposure to capture market-share resilience from in-store clinics; take profit if CVS outperforms WBA by 8% within 3 months, stop-loss if relative underperformance >8%.